Sign In
Buy ATHE
$4.01
-0.0100 (-0.249%)
At Close: Jun 03, 2026
Head-To-Head Contrast: Alterity Therapeutics (NASDAQ:ATHE) & Athira Pharma (NASDAQ:ATHA)
01:44am, Saturday, 14'th Feb 2026
Athira Pharma (NASDAQ: ATHA - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the
Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
07:25am, Friday, 30'th Jan 2026
− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Down 88.6% in December
03:52am, Wednesday, 14'th Jan 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was sh
Financial Survey: Alterity Therapeutics (NASDAQ:ATHE) and Mesoblast (NASDAQ:MESO)
01:08am, Friday, 02'nd Jan 2026
Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) and Mesoblast (NASDAQ: MESO - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companie
Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
07:25am, Wednesday, 12'th Nov 2025
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
07:25am, Friday, 31'st Oct 2025
Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose level Positive data from ATH434-202 open-label trial demonstrates similar treatment effect in advanced
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the Phase 2 trial results – – State-of-the-art neu
Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders
07:35am, Thursday, 02'nd Oct 2025
– Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –
Alterity Therapeutics Raises A$20.0 million in Strategic Placement
07:35am, Monday, 08'th Sep 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to d
Alterity Therapeutics to Present at the Biotech Showcase
07:25am, Tuesday, 02'nd Sep 2025
MELBOURNE, Australia and SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
07:25am, Wednesday, 30'th Jul 2025
Highlights Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA) Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA Presented ad
Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy
07:25am, Monday, 28'th Jul 2025
– ATH434 Demonstrated Clinical Benefit on the Unified MSA Rating Scale and Global Measures of Neurological Symptoms –
Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study
07:25am, Thursday, 24'th Jul 2025
– Peer-reviewed publication in Annals of Clinical and Translational Neurology highlights the use of the MSA Atrophy Index developed to diagnose and track disease progression in Multiple System Atrop
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
07:25am, Monday, 23'rd Jun 2025
MELBOURNE, Australia and SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity Therapeutics Prominently Featured at the International MSA Congress
07:35am, Monday, 12'th May 2025
– ATH434 Phase 2 data demonstrated clinically meaningful efficacy on multiple clinical endpoints – – MSA Atrophy Index (MSAai) enhances MSA diagnosis and monitoring – – bioMUSE Study shows h
